Article

Aggressive Cholesterol Lowering Therapy May Reverse Atherosclerosis

Intensive treatment to LDL-C reduces CIMT in patients with type 2 diabetes, according to a secondary analysis from the SANDS trial.

Intensive treatment to lower low-density lipoprotein cholesterol (LDL-C) reduces carotid intima-media thickness (CIMT) in patients with type 2 diabetes, according to a secondary analysis from the Stop Atherosclerosis in Native Diabetics Study (SANDS) trial.

Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
Related Content
US FDA logo in black over a white background. | Credit: US Food and Drug Administration
November 23rd 2024

FDA Approves Acoramidis (Attruby) for ATTR-CM

Patrick Campbell
Diabetes Dialogue: News and Updates in Diabetes at AHA 2024
November 21st 2024

Diabetes Dialogue: News and Updates in Diabetes at AHA 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Steve Nissen, MD | Credit: Cleveland Clinic
November 18th 2024

Zerlasiran 60-Week Data Reinforce Lp(a) Reductions Observed in ALPACAR-360

Patrick Campbell
Diabetes Dialogue: Diabetes Tech Updates in October 2024
November 11th 2024

Diabetes Dialogue: Diabetes Tech Updates in October 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Bumetanide Nasal Spray Equivalent to Oral, IV Forms for Heart Failure| Image Credit: American Heart Association
November 18th 2024

Bumetanide Nasal Spray Equivalent to Oral, IV Forms for Heart Failure

Connor Iapoce
Sacubtril/Valsartan Lowers Risk of Cardiotoxicity Linked to Chemotherapy | Image Credit: American Heart Association
November 18th 2024

Sacubtril/Valsartan Lowers Cardiotoxicity Risk Linked to Chemotherapy

Connor Iapoce
© 2024 MJH Life Sciences

All rights reserved.